Weakened cross-border healthcare directive will disappoint manufacturers of orphan drugs
This article was originally published in Scrip
Executive Summary
The cross-border healthcare directive will not, as previously hoped, give patients with rare diseases the right to access to orphan drugs in other countries when the treatment is not reimbursed in the patient's own member state. Companies producing orphan drugs will not get the financial and legal security they had hoped for.